FBRX Stock Forecast 2025-2026
Distance to FBRX Price Targets
FBRX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Forte Biosciences (FBRX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on FBRX and similar high-potential opportunities.
Latest FBRX Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, FBRX has a bullish consensus with a median price target of $59.00 (ranging from $57.00 to $61.00). Currently trading at $7.34, the median forecast implies a 703.8% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Daniil Gataulin at Chardan Capital, projecting a 731.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FBRX Analyst Ratings
FBRX Price Target Range
Latest FBRX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FBRX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 1, 2025 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $61.00 |
| Jan 21, 2025 | TD Cowen | Yaron Werber | Buy | Initiates | $0.00 |
| Dec 4, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $64.00 |
| Nov 15, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $64.00 |
| Aug 19, 2024 | Chardan Capital | Daniil Gataulin | Buy | Maintains | $3.00 |
| May 30, 2024 | Brookline Capital | Kumaraguru Raja | Buy | Initiates | $4.00 |
| Apr 8, 2024 | Ladenburg Thalmann | Michael Higgins | Buy | Upgrade | $2.75 |
| Sep 20, 2021 | Chardan Capital | Keay Nakae | Neutral | Upgrade | $3.50 |
| Sep 3, 2021 | Truist Securities | Hold | Downgrade | $0.00 | |
| Sep 3, 2021 | B. Riley Securities | Neutral | Downgrade | $0.00 | |
| Sep 3, 2021 | Brookline Capital | Hold | Downgrade | $0.00 | |
| Sep 3, 2021 | Chardan Capital | Sell | Downgrade | $0.00 | |
| Sep 3, 2021 | Ladenburg Thalmann | Neutral | Downgrade | $0.00 | |
| May 14, 2021 | B. Riley Securities | Buy | Initiates | $0.00 | |
| Mar 26, 2021 | Citigroup | Buy | Initiates | $0.00 | |
| Mar 17, 2021 | Chardan Capital | Gbola Amusa | Buy | Maintains | $105.00 |
| Sep 24, 2020 | Chardan Capital | Gbola Amusa | Buy | Maintains | $110.00 |
| Sep 10, 2020 | Chardan Capital | Gbola Amusa | Buy | Maintains | $60.00 |
| Aug 28, 2020 | Chardan Capital | Buy | Upgrade | $0.00 | |
| Aug 28, 2020 | Brookline Capital | Buy | Initiates | $0.00 |
Forte Biosciences Inc. (FBRX) Competitors
The following stocks are similar to Forte Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Forte Biosciences Inc. (FBRX) Financial Data
Forte Biosciences Inc. has a market capitalization of $48.31M with a P/E ratio of -0.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -80.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Forte Biosciences Inc. (FBRX) Business Model
About Forte Biosciences Inc.
Develops therapies for dermatological diseases.
Forte Biosciences generates revenue by advancing its pipeline of innovative biotherapeutic treatments aimed at conditions like atopic dermatitis. The company operates in the clinical-stage of biopharmaceuticals, focusing on developing and testing therapies that fulfill significant unmet needs in dermatology.
Operating within the competitive biotechnology sector, Forte emphasizes cutting-edge research and the development of targeted therapies. As it navigates the rigorous regulatory landscape and progresses through various stages of drug development, it aims to significantly improve clinical practices and patient outcomes in dermatology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
14
CEO
Dr. Paul A. Wagner Ph.D.
Country
United States
IPO Year
2017
Website
www.fortebiorx.comForte Biosciences Inc. (FBRX) Latest News & Analysis
Forte Biosciences (FBRX) has been upgraded to a Zacks Rank #2 (Buy) due to increasing optimism regarding its earnings prospects, indicating potential for stock price movement.
Forte Biosciences' upgrade to Zacks Rank #2 indicates increased earnings expectations, potentially boosting investor confidence and stock demand.
Forte Biosciences (NASDAQ: FBRX) reported a productive 2024, completing a healthy volunteer study and starting a trial for celiac patients, advancing its FB102 development.
Forte Biosciences' progress on FB102 and new clinical trials can drive stock performance, indicating potential revenue growth and investor returns as the drug advances in development.
Forte Biosciences (NASDAQ: FBRX) will present at the Guggenheim SMID Cap Biotech Conference on February 6 and another investor meeting on March 3, led by CEO Paul Wagner, PhD.
Forte Biosciences' presentations at investor meetings highlight its visibility and potential, which can influence investor interest and stock performance in the biopharmaceutical sector.
Forte Biosciences (FBRX) is highlighted as a potential option for short-term investors, having met criteria from a trading strategy focused on fundamentally sound stocks.
Forte Biosciences shows potential for short-term gains due to positive price trends and strong fundamentals, appealing to traders seeking quick profits.
Forte Biosciences (FBRX) is highlighted as a potential short-term investment opportunity, having passed a trading strategy screen for fundamentally sound stocks.
Forte Biosciences shows potential for short-term gains, indicating investor interest and volatility, which could lead to profitable trading opportunities.
Forte Biosciences to Host R&D Day December 3, 2024
4 months agoForte Biosciences (NASDAQ: FBRX) will hold an R&D Day on December 3, 2024, focusing on FB102 for autoimmune diseases, featuring experts in celiac disease, vitiligo, and alopecia areata.
Forte Biosciences' R&D Day will showcase advancements in its autoimmune drug FB102, attracting attention from investors keen on biotech developments and potential growth in this market.
Frequently Asked Questions About FBRX Stock
What is Forte Biosciences Inc.'s (FBRX) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Forte Biosciences Inc. (FBRX) has a median price target of $59.00. The highest price target is $61.00 and the lowest is $57.00.
Is FBRX stock a good investment in 2025?
According to current analyst ratings, FBRX has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.34. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for FBRX stock?
Wall Street analysts predict FBRX stock could reach $59.00 in the next 12 months. This represents a 703.8% increase from the current price of $7.34. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Forte Biosciences Inc.'s business model?
Forte Biosciences generates revenue by advancing its pipeline of innovative biotherapeutic treatments aimed at conditions like atopic dermatitis. The company operates in the clinical-stage of biopharmaceuticals, focusing on developing and testing therapies that fulfill significant unmet needs in dermatology.
What is the highest forecasted price for FBRX Forte Biosciences Inc.?
The highest price target for FBRX is $61.00 from Daniil Gataulin at Chardan Capital, which represents a 731.1% increase from the current price of $7.34.
What is the lowest forecasted price for FBRX Forte Biosciences Inc.?
The lowest price target for FBRX is $57.00 from at , which represents a 676.6% increase from the current price of $7.34.
What is the overall FBRX consensus from analysts for Forte Biosciences Inc.?
The overall analyst consensus for FBRX is bullish. Out of 7 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $59.00.
How accurate are FBRX stock price projections?
Stock price projections, including those for Forte Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.